Official title and information are available only for Plus and Premium subscribers.
Patent Granted Because of the Akt[1] functions above, Akt inhibitors may treat cancers such as neuroblastoma. Some Akt inhibitors have undergone clinical trials. In 2007 VQD-002 had a phase I trial.[26] In 2010 Perifosine reached phase II.[27] but it failed phase III in 2012. Miltefosine is approved for leishmaniasis and under investigation for other indications including HIV.
To see the additional information details please login and subscribe to a Plus or Premium account.
